News Release
FOR IMMEDIATE RELEASE Friday, March 12, 2004 |
Contact: HHS Press Office (202) 690-6343
|
HHS Moves to Acquire New Anthrax Vaccine for Stockpile
The Department of Health and Human Services has requested proposals from industry for the development, testing and manufacture of a new anthrax vaccine.
"As the lead federal agency for public health and medical response, we are moving forward to insure our nation is protected against anthrax," HHS Secretary Tommy G. Thompson said. "The new vaccine will be added to our emergency stockpile of antibiotics and other critical medical supplies."
HHS intends to acquire up to 75 million doses of the recombinant protective antigen (rPA) anthrax vaccine for the Strategic National Stockpile. The vaccine would be used to protect the public against a terrorist attack in which anthrax spores are released.
The new rPA anthrax vaccine has already been shown to be stronger and more effective than the vaccine being used today. It will require fewer doses per individual to provide immunity against the effects of anthrax inhalation.
Companies interested in bidding for the contract must submit their proposals for review by April 16, 2004. Each proposal must clearly demonstrate the bidder's ability to comply with a strict set of guidelines listed in the department's solicitation.
###
Note: All HHS press releases, fact sheets and other press materials are available at http://www.hhs.gov/news.
Last Revised: March 12, 2004
|